Probiodrug AG (Probiodrug), today announced that Dr.
Hendrik Liebers, chief financial officer of Probiodrug, will be
presenting a corporate update at the annual BioEquity Europe conference,
being held 21-22 May 2014. Dr. Liebers' presentation will take place at
4:20pm local time on 21 May 2014 at the Hilton Amsterdam Hotel in the
Bioequity Europe is an annual collaborative gathering of the corporate
and investment communities for the European life sciences. It is
designed to be the premier European venue for biopharma companies
looking to attract capital and expand ther business development
efforts. For more information on the conference, please visit www.biocentury.com/conferences/bioequityeurope.
About Probiodrug AG
Probiodrug is a biopharmaceutical company dedicated to the discovery and
development of novel therapeutic solutions to treat people with
Alzheimer's disease. The Company has medical use and composition of
matter patents related to the inhibition of glutaminyl cyclase,
providing the Company with a dominant position in this field of
research. Probiodrug is backed by institutions such as BB Biotech,
Edmond de Rothschild Investment Partners, Goodvent/IBG, HBM, TVM
Capital, Life Sciences Partners, Biogen Idec New Ventures, CFH Group,
funds managed by Wellington Management and private investors.
Probiodrug's core capabilities are based on its long-standing expertise
in the elucidation of the structure and function of enzymes which play a
central role in the maturation of hormones. Probiodrug was founded in
1997 by Prof. Dr. Hans-Ulrich Demuth and Dr. Konrad Glund. For more
information, please visit www.probiodrug.de.
[ Back To NFVZone's Homepage ]